ASTRAZENECA PHARMACEUTICALS LP - 2 LINE ITEMS FOR ANTI-INTERLEUKIN MONOCLONAL ANTIBODIES FOR ASTHMA (BENRALIZUMAB). AWARDED FOR A BASE YEAR OF 2/15/2021 TO 2/14/2022 PLUS FOUR ONE-YEAR OPTION PERIODS.
Key Details
Description
2 LINE ITEMS FOR ANTI-INTERLEUKIN MONOCLONAL ANTIBODIES FOR ASTHMA (BENRALIZUMAB). AWARDED FOR A BASE YEAR OF 2/15/2021 TO 2/14/2022 PLUS FOUR ONE-YEAR OPTION PERIODS.
Context & Analysis
On Jan 20, 2026, Department of Veterans Affairs to ASTRAZENECA PHARMACEUTICALS LP for 2 line items for anti-interleukin monoclonal antibodies for asthma (benralizumab). awarded for a base year of 2/15/2021 to 2/14/2022 plus four one-year option periods.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 3 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.